LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ

Guy E H M Rutten, Cees J Tack, Thomas R Pieber, Abdurrahman Comlekci, David Dynnes Ørsted, Florian M M Baeres, Steven P Marso, John B Buse, LEADER Investigators, Guy E H M Rutten, Cees J Tack, Thomas R Pieber, Abdurrahman Comlekci, David Dynnes Ørsted, Florian M M Baeres, Steven P Marso, John B Buse, LEADER Investigators

Abstract

Aims: To determine whether US and European participants in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial differ regarding risk factors for cardiovascular mortality and morbidity.

Methods: Baseline data, stratified for prior cardiovascular disease (CVD), were compared using multivariable logistic regression analysis to establish whether region is an independent determinant of achieved targets for glycated hemoglobin (HbA1c), blood pressure (BP), and low-density lipoprotein (LDL)-cholesterol.

Results: Independent of CVD history, US participants were more often of non-White origin and had a longer history of type 2 diabetes, higher body weight, and higher baseline HbA1c. They had substantially lower systolic and diastolic BP, and a marginally lower LDL-cholesterol level. Fewer US participants were diagnosed with left ventricular dysfunction. In the largest group of patients, those with prior CVD and the highest cardiovascular risk, US participants were more often female, had a higher waist circumference, and had a decreased estimated glomerular filtration rate, but less frequently prior myocardial infarction or angina pectoris.

Conclusions: There were baseline differences between US and European participants. These differences may result from variation in regional targets for cardiovascular risk factor management, and should be considered in the analysis and reporting of the trial results. Clinical trial identifier: ClinicalTrials.gov, NCT01179048.

Keywords: Cardiovascular outcome trial; External validity; Generalizability; Heterogeneity; Type 2 diabetes.

References

    1. Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, Pocock S, Steinberg WM, Bergenstal RM, Mann JF, Ravn LS, Frandsen KB, Moses AC, Buse JB. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166:823–830. doi: 10.1016/j.ahj.2013.07.012.
    1. Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383:2008–2017. doi: 10.1016/S0140-6736(14)60794-7.
    1. Saunders C, Byrne CD, Guthrie B, Lindsay RS, McKnight JA, Philip S, Sattar N, Walker JJ, Wild SH, Scottish Diabetes Research Network Epidemiology Group External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet Med. 2013;30:300–308. doi: 10.1111/dme.12047.
    1. Rivers D, August EM, Sehovic I, Lee Green B, Quin GP. A systematic review of the factors influencing African American’s participation in cancer clinical trials. Contem Clin Trials. 2013;35:13–32. doi: 10.1016/j.cct.2013.03.007.
    1. Weiss CO, Boyd CM, Wolff JL, Leff B. Prevalence of diabetes treatment effect modifiers: the external validity of trials of older adults. Aging Clin Exp Res. 2012;24:370–376. doi: 10.1007/BF03325268.
    1. Kandzari DE, Roe MT, Chen AY, Lytle BL, Pollack CV, Jr, Harrington RA, Ohman EM, Gibler WB, Peterson ED. Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2005;149:474–481. doi: 10.1016/j.ahj.2004.11.014.
    1. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355:1064–1069. doi: 10.1016/S0140-6736(00)02039-0.
    1. Gheorghe A, Roberts TE, Ives JC, Fletcher BR, Calvert M. Centre selection for clinical trials and the generalisability of results; a mixed methods study. PLoS One. 2013;8:e56560. doi: 10.1371/journal.pone.0056560.
    1. Stone MA, Wilkinson JC, Charpentier G, Clochard N, Grassi G, Lindblad U, Müller UA, Nolan J, Rutten GE, Khunti K, GUIDANCE Study Group Evaluation and comparison of guidelines for the management of people with type 2 diabetes from eight European countries. Diab Res Clin Pract. 2010;87:252–260. doi: 10.1016/j.diabres.2009.10.020.
    1. American Diabetes Association Standards of Medical Care in Diabetes—2010. Diabetes Care. 2010;33:S4–S10. doi: 10.2337/dc10-S004.
    1. Kent DM, Rothwell PM, Ioannidis JPA, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment affects in clinical trials; a proposal. Trials. 2011;11:85. doi: 10.1186/1745-6215-11-85.
    1. Wagner M, Balk EM, Kent DM, Kasiske BL, Ekberg H. Subgroup analyses in randomized controlled trials: the need for risk stratification in kidney transplantation. Am J Transplant. 2009;9:2217–2222. doi: 10.1111/j.1600-6143.2009.02802.x.
    1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR, American Diabetes Association (ADA) European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012;35:1364–1379. doi: 10.2337/dc12-0413.
    1. American Diabetes Association Clinical Practice Recommendation. Diabetes Care. 2014;37:S1. doi: 10.2337/dc14-S001.
    1. Dorresteijn JA, Visseren FL, Ridker PM, Wassink AM, Paynter NP, Steyerberg EW, van der Graaf Y, Cook NR. Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ. 2011;343:d5888. doi: 10.1136/bmj.d5888.
    1. van der Leeuw J, Visseren FL, Woodward M, Zoungas S, Kengne AP, van der Graaf Y, Glasziou P, Hamet P, MacMahon S, Poulter N, Grobbee DE, Chalmers J. Predicting the effect of blood pressure lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation. Hypertension. 2015;65:115–121. doi: 10.1161/HYPERTENSIONAHA.114.04421.
    1. Sardar P, Udell JA, Chatterjee S, Bansilal S, Mukherjee D, Farkouh ME. Effect of intensive versus standard blood glucose control in patients with type 2 diabetes in different regions of the world: systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2015;4:e001577. doi: 10.1161/JAHA.114.001577.
    1. Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM. Holman RR; TECOS Executive Committee. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Diabetes Obes Metab. 2015;17:395–402. doi: 10.1111/dom.12441.
    1. Hardin DS, Rohwer RD, Curtis BH, Zagar A, Chen L, Boye KS, Jiang HH, Lipkovich IA. Understanding heterogeneity in response to antidiabetes treatment: a post hoc analysis using SIDES, a subgroup identification algorithm. J Diabetes Sci Technol. 2013;7:42. doi: 10.1177/193229681300700219.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa